Abbott Laboratories (NYSE:ABT) has agreed to pay more than $384 million to resolve U.S. Justice Department allegations that it knowingly produced infant formula in potentially contaminated environments at its Michigan and Arizona facilities, including allegations of inadequate testing and failure to disclose positive contamination tests to regulators. The settlement resolves civil claims without an admission of wrongdoing or a finding of liability, while the related criminal investigation has been closed. The case stems from Abbott’s 2022 Similac recall, which followed contamination concerns at its Sturgis, Michigan plant and contributed to a nationwide infant-formula shortage. Abbott maintains that no unopened, distributed formula tested positive for contamination.
Financially, the $384 million payment is significant but manageable relative to Abbott’s scale. Abbott generated $12.6 billion of sales in Q2 2026 and raised its full-year adjusted EPS outlook to $5.45-$5.60, while returning $2.1 billion to shareholders during the quarter. The more important issue is therefore not the one-time cash settlement itself, but whether the resolution removes a major overhang around Abbott’s Nutrition business and limits further regulatory or litigation costs.
Formula Settlement May Let Abbott Refocus on Broader Growth
The strongest bullish argument is that the settlement could mark an important step toward containing the financial and regulatory fallout from the 2022 formula crisis. The Justice Department says the agreement resolves the civil claims and that the related criminal investigation has been closed, reducing the probability of another major escalation from this particular matter. For investors, that provides greater visibility around the potential cash costs associated with the episode and allows Abbott Laboratories to focus on its broader portfolio rather than continuing to absorb uncertainty around the Sturgis-related controversy.
The settlement also appears manageable against Abbott’s earnings and cash-generation capacity. With 2026 adjusted EPS guidance of $5.45-$5.60 and Q2 sales of $12.6 billion, a $384 million settlement represents a material but not balance-sheet-threatening charge for a company of Abbott’s size. More importantly, Abbott recently resolved a separate portion of litigation involving specialty formulas for preterm infants for approximately $670 million, covering the Gill case and claims involving roughly 2,000 individuals. If these settlements substantially reduce the remaining litigation uncertainty surrounding infant nutrition, the market could increasingly treat the issue as a contained legacy liability rather than a recurring threat to Abbott’s valuation.
There is also evidence that Abbott Laboratories’s broader business remains capable of absorbing setbacks in Nutrition. The company reported 13% sales growth and 4.8% comparable sales growth in Q2, while maintaining its 6.5%-7.5% full-year comparable-sales growth forecast. That diversification matters because it reduces the likelihood that problems surrounding infant formula alone materially derail consolidated growth. The settlement could therefore be viewed as a cost of closing out a legacy problem while Abbott’s larger medical-device, diagnostics and pharmaceutical businesses continue supporting earnings growth.
Formula Litigation Could Keep Weighing on Abbott’s Risk Profile
The principal bearish concern is that the $384 million payment reinforces the seriousness of the underlying manufacturing and regulatory allegations. The Justice Department alleged not simply an isolated contamination event, but deficiencies involving product testing and the disclosure of positive contamination tests to regulators. Even without an admission of wrongdoing, such allegations can damage trust in a category where safety and reliability are especially important. Abbott’s infant-nutrition franchise depends heavily on consumer, hospital, and regulatory confidence, so reputational damage could have consequences beyond the immediate settlement.
The 2022 episode has also already demonstrated that manufacturing disruption in Abbott Laboratories’s formula business can have consequences far beyond a single product recall. The Sturgis plant closure contributed to a nationwide infant-formula shortage, and Abbott has subsequently faced continuing litigation related to its specialty formulas. Abbott’s June 2026 10-Q said numerous NEC-related lawsuits remained outstanding and disclosed that a $495 million Missouri jury award had been affirmed on appeal, although Abbott was seeking further review. The existence of this broader litigation backdrop means investors cannot necessarily treat the $384 million settlement as the final cost of Abbott’s infant-formula controversies.
There is also a potential margin and cash-flow consideration if Abbott Laboratories must continue increasing quality-control, testing and compliance spending. Abbott has previously described enhanced pre- and post-production testing when restarting Similac production at Sturgis. Additional safeguards may be necessary to rebuild confidence, but they can raise manufacturing costs and reduce the economic benefit of the Nutrition business. If future recalls, settlements or legal judgments emerge, the cumulative cash burden could become more material than the latest $384 million payment suggests.
Conclusion
Abbott Laboratories’s $384 million settlement is financially manageable and reduces uncertainty by closing the DOJ case, but broader infant-formula litigation remains a risk. Overall, the news is modestly positive if it marks meaningful legal closure, but it does not eliminate Abbott’s remaining regulatory, reputational, and litigation exposure.
READ NEXT: Bank of America Warns of 10%+ Drop in Q3 Investment Banking Fees and BioNTech’s Lung Cancer Drug Shows Signs of a Major Breakthrough
This article is originally published at Insider Monkey.
Hedge Fund Resource Center